Navigation Links
DURECT Announces Resignation of Chief Medical Officer
Date:6/2/2011

CUPERTINO, Calif., June 2, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer, Chief Medical Officer and Executive Vice President, Corporate Strategy has resigned effective June 21, 2011 to pursue other opportunities.  Dr. Stauffer and DURECT have entered into a consulting agreement through December 31, 2011.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

"We appreciate all of Joe's efforts over the last two years, most notably in designing the U.S. pivotal Phase III clinical study for POSIDUR® (BESST), look forward to his continuing assistance through a consulting arrangement and wish him all the best in his future endeavors," stated James E. Brown, President and CEO.  "We are confident that the clinical and regulatory team we have in place will continue to execute in advancing our pipeline of programs in development."

"I enjoyed my time at DURECT and believe in the medical benefits of the company's pipeline," said Joseph Stauffer, D.O., M.B.A.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017  Harrington Discovery Institute at ... – part of The Harrington Project for ... partnership Scholars selected in collaboration with Alzheimer,s Drug ... University of Oxford. Harrington Discovery ... to advance discoveries into new medicines that will ...
(Date:1/16/2017)... Jan. 16, 2017  According to Kalorama Information, ... is valued at $4.9 billion for 2016.  The ... with an aging population with significant diagnostic needs, ... is propelling the market for the modality.  The ... Markets , focuses on the worldwide market, providing ...
(Date:1/16/2017)... and PUNE, India , January 16, ... Allied Market Research, titled, "Vital Signs Monitoring Devices Market by ... 2014-2022", projects that the global vital signs monitoring devices market ... to reach $5,491 million by 2022, growing at a CAGR ... was the leading regional market in global vital ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been ... of 100 organizations honored for their accomplishments in the field of midmarket financial software. ... leadership and recognition, and innovation. Selection is not based on revenue and those firms ...
(Date:1/15/2017)... ... ... LLC is announcing the release of an updated version of their top selling clipper, ... has wide jaws that will accommodate nails up to 4mm in thickness . Nails ... is reinforced for extra strength when pressing down on dense nails which can be a ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... ... choice of best physicians in eight Bay Area counties for 2017. Almost 1,000 ... healthcare research company managing the award process. Results were announced the magazine’s ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... Montclair, NJ is pleased to announce that it will be assisting HackensackUMC Mountainside ... Montclair and Glen Ridge townships, servicing all surrounding towns. The firm will be ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products and services that ... is now available on Apple as a fun, free emoji sticker pack for iMessage. ... of the ten color coded values on The Emoji Scale. , On Apple: ...
Breaking Medicine News(10 mins):